Opdivo's benefit extends for kidney cancer & parietal cancer

The HIRA announces new standards and will take effect from the 1st of next month

Also includes changes in the subject of Kisqali combined therapy administration

As domestic No.

 

1 immuno-cancer drug "Opdivo (Nivolumb)" renewed its contract with RSA, the benefit standard has also been expanded.

 

The HIRA will issue a "proposal to revise the announcement of drugs prescribed and dispensed to cancer patients" and will inquire about their opinions by the 25th.

 

If there is no disagreement, the benefit will be applied from the 1st of next month after the Health Insurance Policy Review Committee's resolution this week.

 

According to Opdivo-related standards, Yervoy (Ipilimumab) and combined therapy were recognized in the first stage of kidney cancer, and it was recognized in the second or more solo therapy for parietal cancer and the third or more Hodgkin lymphoma.

 

Yervoy 50mg and Yervoy 200mg was licensed as a "medium- or high-risk, progressive neocarcinoma treatment with Optdivo and combined therapy," which has no previous treatment experience.

 

As a result of the review of benefit criteria for Opdivo and Yervoy combination therapy, NCCN guidelines recommend preferred category 1 for primary treatment of moderate or high-risk transparent cell carcinoma, and 'I, A' for ESMO guidelines.

 

The benefit standard was set by limiting the tissue type of kidney cancer to patients with moderate or high-risk IMDC risk classification to clear cell carcinoma.

 

Based on Opdivo's criteria for treatment of parietal cell carcinoma, the NCCN guidelines recommend "second-line and subsequent therapy" as "category 1" for recurrent, non-abstructive or metastatic cancers during or after platinum-based chemotherapy.

 

However, if the expression rate of PD-L1 is less than 1% in open-label clinical trials, the standard was set only when the expression rate of PD-L1 was 1% or higher considering the median value of the entire survival period (mOS 5.7 months vs.

 

5.8 months) similar to alternative therapy.

 

HSCT is also recognized for typical Hodgkin lymphoma patients who have recurred or progressed with Brentuximab Vedotin.

 

Children were also included in the list, considering the nature of Hodgkin's lymphoma disease and the addition of permission for children in excluded countries.

 

According to the HIRA's review, premenopausal patients intentionally performed ovarian resection to induce menopause for use in line with the current benefit criteria, or the expected additional financial requirements were not significant.